Shanghai RAAS to hold EGM on governance changes, new director appointments

Shanghai RAAS Blood Products will convene its third extraordinary general meeting of 2025 on December 15, 2025, to address significant governance revisions. Shareholders will vote on proposed amendments to the company's Articles of Association, Shareholder Meeting Rules, Board of Directors Meeting Rules, Independent Director Work System, Related Party Transaction Management Measures, External Guarantee Management Measures, and Board of Directors Remuneration and Appraisal System. These changes aim to enhance the company’s internal controls and compliance.

Further proposals include updates to the Management Measures for Raised Funds, the Three-Year (2024-2026) Shareholder Return Plan, and the Management System for Insider Information. Additionally, the meeting will consider revisions to policies concerning directors' and senior management's stock holdings, information disclosure, the board secretary's work rules, and external investment management.

The agenda also features the appointment of new independent and non-independent directors, following the resignation of Mr. Amarant Martínez Carrió. Ms. Esther Fages Contel has been nominated as a non-independent director, and Ms. Chen Yan has been nominated as an independent director, pending regulatory approval. The company will also abolish several older internal regulations.